Search PubMed⌕ Search

Biomedical subjects

J Meynadier

Publications and source records attributed to J Meynadier.

At least 55 records · Page 3Linked to original sources
PubMed1995

[Lichen planus and hepatitis C virus. Apropos of 5 new cases].

Lichen planus is an immunologically mediated skin or mucous disease, which has recently been described in some patients with hepatitis C virus-related liver disease. We report 5 new cases of the association of hepatitis C with lichen planus, to be added to the 15 cases published in the literature. The sex ratio (female/male) was of 1.2. Lichen planus occurred more frequently in chronic active hepatitis (2/3 of cases) than in cirrhosis (1/3 of cases). Lichen planus manifestations were only mucous (30%), only cutaneous (40%) or both (30%). Mucous lesions were mainly observed in patients with cirrhosis (3/4 of cases). The onset of skin and hepatic manifestations was variable, with liver disease as the most frequent revealing symptom (60%). The influence of interferon remains unclear. However, it seemed to trigger more than to relieve lichen planus.

Adrenal Cortex Hormones↗
PubMed1995

[Primary cutaneous nocardia asteroides nocardiosis in an immunocompromised patient].

INTRODUCTION: Nocardiasis is caused by a germ belonging to the Actinomycetales order. Skin disease usually occurs as a secondary localization of a pulmonary infection in an immunocompromised patient. Purely cutaneous lesions usually occur in immunocompetent subjects. CASE REPORT: We observed primary cutaneous nocardiasis due to N. asteroides with a cold abscess in a patient with a pemphigoid given immunodepression treatment. DISCUSSION: Primary cutaneous nocardiasis can occur by direct contamination of a skin wound. In our patient with a pemphigoid given immunodepression treatment, the erosion of a pemphigoid bulla and general corticosteroid treatment favoured the localized infection. Cure could not be obtained until after 7 months treatment. This long course can be explained by the need to continue high-dose general corticosteroids to control the pemphigoid.

Aged↗
PubMed1994

Acquired progressive lymphangioma.

Acquired progressive lymphangioma (APL) is a rare, benign proliferation of lymphatic capillary origin, which is characterized histologically by dermal vascular channels and a 'dissection of collagen' appearance. We describe a 30-year-old patient with an extensive, refractory APL on the right breast, which slowly developed over a period of 23 years. Pathologists and dermatologists should be aware of this entity, as early surgical treatment may be totally curative when the lesion is limited in size.

Breast Neoplasms↗
PubMed1994

[Scleroderma of the shoulders after treatment with combined bleomycin and radiotherapy].

INTRODUCTION: There are many causes of scleroderma. We observed a case of scleroderma involving the shoulder and neck area after combined bleomycin and radiotherapy. CASE REPORT: After six cycles of a CHOP-bleo protocol followed by radiotherapy for lymph node lymphoma, a female patient presented scleroderma involving the shoulders and neck area. Total bleomycin dose was 252 mg. DISCUSSION: Among the imputable factors, particularly extrinsic factors, in a series of 33 cases of different chemotherapy protocols published by Peters et al. in 1988, we retained the bleomycin radiotherapy administration sequence as the cause of this complication. Given after bleomycin, radiotherapy could increase the risk of scleroderma.

Adult↗
PubMed1994

[Drug therapy of pain in oncology: keep it simple!].

Pain is the most common symptom in patients suffering from cancer, in particular for advanced diseases. Unfortunately, one third of the patient do not benefit from optimal pain control. One must stress the importance of defining the etiology of pain and subsequently its pathophysiology. This thorough evaluation can help to formulate a proper strategy for a treatment of pain that could be adapted to the disease evolution. A multidisciplinary approach with respect to the WHO prescribing criteria is the most appropriate way to control severe cancer pain syndromes.

Analgesics↗
PubMed1993

[Rosacea].

Rosacea is a frequent disease which occurs mostly in women with dry skin and much more rarely in men with greasy skin. In women, rosacea is heralded, around the age of 20 years, by intermittent facial erythema, and this is followed by the gradual development of permanent erythema (erythrosis) with telangiectasia (couperose) and later on, around the age of 40, very unsightly papulo-pustules (papular rosacea, improperly called acne rosacea). In men, these successive stages are less frequent, but progressive dilatation of the nose due to sebaceous gland overgrowth may occur (rhinophyma). Rosacea is caused by vascular abnormalities not completely determined, and also, at the papulo-pustural stage, by a small parasite called Demodex folliculorum. Treatment rests on hygienic and dietary rules and vasoconstrictor drugs at the erythema stage, then on fine electrocoagulation or pulsed dye laser to suppress couperose and on the prescription of long-term low-dose tetracycline, sometimes preceded by a 2-month course of metronidazole to remove the papulo-pustules. Rhinophyma is treated by surgery. The results obtained are remarkable, at least on couperose, papulo-pustules and rhinophyma.

Adult↗
PubMed1993

Patch test reactions to mite antigens: a GERDA multicentre study. Groupe d'Etudes et de Recherches en Dermato-Allergie.

We performed patch tests with Dermatophagoides pteronyssinus (Dp) antigens from 2 different sources in 355 non-randomly selected patients with atopic dermatitis (AD) and 398 subjects of a control group. The study demonstrated that contact sensitization to mites occurred in an appreciable % of AD cases (20.8%), using commonly available assay products. The differences recorded between the 2 materials tested were related to the concentration of P1 antigen. Non-atopic patients rarely showed positive reactions to Dp (0.75%), when strict criteria for readings were applied and if 2 readings were performed. Patients with positive patch tests did not necessarily show positive immediate skin tests. It would be useful to carry out tests systematically in atopic patients, even if it is not yet known what modern treatment would be best for the patient. Laboratories still do not provide standardized house dust mite preparations--measuring and codifying their biological activity--for use in patch tests. It is to be hoped that the extension of this type of test will lead to the production of better test materials, in syringes with homogeneous dispersion and concentration.

Administration, Inhalation↗
PubMed1992

[Phototherapy of photodermatoses].

Paradoxical as it may seem, phototherapy, and in particular PUVA therapy, is of considerable interest in the treatment of such photodermatoses as polymorphous light eruptions, solar urticaria and remanent photosensitivity syndrome. When used rationally, with the appropriate therapeutic regimen and under close monitoring of the parameters, these treatments give very satisfactory results in preventing the occurrence of photo-induced skin eruptions.

Humans↗
PubMed1992

Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.

BACKGROUND: The biologically active form of vitamin D3, calcitriol, may offer a new therapeutic approach to psoriasis. Calcipotriol, a new vitamin D3 analogue, is at least 100 times less calcemic than calcitriol. OBJECTIVE: Our purpose was to study the efficacy and safety of calcipotriol in the treatment of psoriasis vulgaris. METHODS: In a right/left comparative, double-blind study, treatment with calcipotriol ointment (50 micrograms/gm) twice daily and placebo was given for 4 weeks. The preferred treatment was continued, without opening the code, for another 4 weeks. Efficacy, as measured by the Psoriasis Area and Severity Index and by the investigator's and patient's global assessment, and safety were assessed every 2 weeks. RESULTS: The mean Psoriasis Area and Severity Index fell in 4 weeks from 14.2 to 6.3 with calcipotriol and from 14.1 to 9.2 with placebo (p < 0.001; 95% confidence interval for difference: 1.78-->3.94). Local side effects were equally common with calcipotriol and placebo. The mean serum calcium remained unchanged. CONCLUSION: Topical application of up to 50 gm of calcipotriol ointment per week was found to be an effective and safe treatment of psoriasis vulgaris.

Adult↗
PubMed1992

Treatment of psoriasis with a 311-nm UVB lamp.

In a left-right comparative study, the Philips TL-01 sunlamp, a new UVB fluorescent lamp, was evaluated in 15 patients with symmetrical psoriasis. One half of the body was treated in a cabin containing TL-01 lamps, and the other half in a cabin containing TL-12 lamps. The patients were treated three times/week, and the study was conducted in a randomized, double-blind fashion. The percentage response of psoriatic lesions was determined on the tenth and twentieth exposures. The therapeutic effect of the TL-01 lamps was superior to that of the TL-12 lamps, and treatment was better tolerated, particularly with regard to episodes of burning. This new lamp appears to provide more effective and safer phototherapy for psoriasis.

Adult↗
PubMed1992

[Narrow-band UVB phototherapy (Philips TL01 lamps) in psoriasis].

The authors report the results of an open study conducted on 53 patients with psoriasis treated by narrow-band UVB phototherapy, using Philips' TL01 lamp. With a simple procedure which did not require MED determination this treatment gave satisfactory results in 92 p. 100 of the cases, with mild burns in only 9 p. 100. The morphological type of psoriasis (patchy, guttate or nummular) had no influence on the therapeutic result, but the degree of infiltration of the lesions and their location on the lower limbs proved to be a factor of relative resistance. In most patients the results were obtained in 20 sessions with a mean cumulative dose of 20.19 +/- 2.7 J/cm2. Some patients had an additional treatment of 6 sessions. The results obtained with Philips' TL01 lamp were as satisfactory as those obtained with the conventional UVB lamps, but the TL01 lamp seemed to be easier to handle and better tolerated, which gives them some advantages over the latter.

Adolescent↗
PubMed1991

[Light-induced aging of the skin].

Ageing of the skin results from the synergistic effects of intrinsic, genetically determined factors and extrinsic factors the most important of which is chronic exposure to sunlight. The cumulative effects of ultraviolet radiations are responsible for specific dermo-epidermal alterations (actinodermatitis) with its two main manifestations: actinic elastosis characterized by accumulation of dystrophic fibres in the dermis, and lesions of senile keratosis which may become carcinomas. The so-called "premature ageing of the skin" can be alleviated by cosmetic treatments, photoprotective measures and vitamin A derivatives; regular applications of retinoic acid (vitamin A acid, tretinoin) can result in partial regression of actinodermatitis.

Epidermis↗
PubMed1991

The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.

Forty-five patients with cutaneous T-cell lymphomas (CTCL), 32 with mycosis fungoides (MF) and 13 with Sézary syndrome (SS), were treated with interferon-alpha 2a (IFN-alpha 2a) (6-9 x 10(6) IU daily) for 3 months. Those responding to treatment were then treated with interferon-alpha alone (6-9 x 10(6) IU three times weekly), and non-responders received a combination of etretinate (0.5 mg/kg/day) and IFN-alpha 2a in similar concentrations. After 12 months of treatment, 28/45 patients (62.2%) were in complete or partial (greater than 50%) remission. Of these, 17 (60.7%) were receiving IFN-alpha alone and 11 the combined interferon-retinoid therapy. Of the patients with MF stage I and II, 20/25 were responders (12 receiving IFN-alpha alone and eight on combined therapy), whereas only 8/20 with stage IV or SS responded to treatment (five receiving IFN-alpha 2a alone and three combined therapy). These results suggest that the association of etretinate with low-dose recombinant IFN-alpha 2a is an effective means of treating epidermotropic CTCL, particularly in the early stages.

Adolescent↗